Trial Profile
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-sensitive, HER-2 Negative Operable Breast Cancer. A Double Blind Randomized Phase II Study With Biomarker Evaluation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Letrozole
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms LET-LOB
- Sponsors GlaxoSmithKline
- 04 Jun 2013 Biomarker results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jul 2011 Preliminary results have been reported at ASCO 2011.
- 01 Apr 2011 Primary endpoint 'Objective-clinical-response-rate' has not been met.